We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
Read MoreHide Full Article
Key Takeaways
AbbVie shares jumped 6% last week, adding $23.5B in market value amid sector-wide investor optimism.
Pfizer's new pricing and tariff deal with the Trump administration boosted sentiment across Big Pharma.
ABBV plans over $10B in U.S. investments, including a $70M expansion at its Worcester, MA, facility.
Shares of AbbVie (ABBV - Free Report) gained 6% last week, translating to roughly $23.5 billion in market value. This upside was primarily driven by investor optimism around the broader pharmaceutical sector after Pfizer (PFE - Free Report) announced a landmark agreement with the Trump administration.
Through its deal, Pfizer addresses the two biggest concerns that currently surround the broader pharmaceutical sector — drug pricing and tariffs. While the company will align the prices of its marketed drugs with those in other developed countries, it will also extend substantial discounts to American citizens who purchase its products through TrumpRx.gov, a new federal purchasing platform that is expected to go live next year.
In return, Pfizer will receive a three-year exemption from import tariffs on pharmaceutical ingredients, contingent upon expanding its domestic manufacturing operations. In this regard, PFE intends to invest an additional $70 billion over the next few years to strengthen its U.S. research and production footprint.
The above announcement has improved investor outlook around the overall pharma sector, as it signals a more cooperative stance between the Trump administration and Big Pharma. We view the Pfizer deal as a turning point that could ease regulatory and pricing pressures that have weighed on the industry since the onset of this year. Stocks of several major drugmakers, including AbbVie, moved higher last week on expectations that similar policy incentives and tariff exemptions could soon extend to other industry players, especially the ones that have already committed to investing billions to boost domestic investments.
Like Pfizer, AbbVie has also committed to a broader investment plan in the country. Earlier this year, the company announced plans to invest more than $10 billion over the next decade. Under this plan, ABBV recently announced a $70 million investment to increase the bioresearch and manufacturing capabilities at its Worcester, MA, facility. This new facility will boost domestic biologics manufacturing capacity to meet increased global demand and support U.S. production of current and next-generation oncology and immunology medicines.
Investors Express Optimism Around Pharma Sector
The Trump administration’s deal with Pfizer removed a major obstacle for the broader pharma industry. Besides AbbVie, shares of other pharma bigwigs like AstraZeneca (AZN - Free Report) and Eli Lilly (LLY - Free Report) , among others, also surged on the belief that they could follow PFE’s example and sign similar deals, largely benefitting the broader pharma sector. Both Lilly and AstraZeneca gained around 16% in the past week.
AstraZeneca announced plans to invest $50 billion in U.S. manufacturing and research and development (R&D) by 2030. AZN’s plan includes a new multi-billion-dollar manufacturing facility to be set up in Virginia.
Lilly has announced plans to invest $27 billion to develop four new manufacturing sites in the United States by 2025.
Several other companies like J&J, GSK, Novartis and Roche have also committed billions to U.S. manufacturing and R&D investments.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a premium to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.91 times forward earnings, slightly higher than its industry’s average of 15.96. The stock is also trading above its five-year mean of 13.09.
Image Source: Zacks Investment Research
EPS estimates for 2025 and 2026 have increased in the past 60 days.
Image: Bigstock
AbbVie Stock on the Move: What Sparked the 6% Jump in the Past Week?
Key Takeaways
Shares of AbbVie (ABBV - Free Report) gained 6% last week, translating to roughly $23.5 billion in market value. This upside was primarily driven by investor optimism around the broader pharmaceutical sector after Pfizer (PFE - Free Report) announced a landmark agreement with the Trump administration.
Through its deal, Pfizer addresses the two biggest concerns that currently surround the broader pharmaceutical sector — drug pricing and tariffs. While the company will align the prices of its marketed drugs with those in other developed countries, it will also extend substantial discounts to American citizens who purchase its products through TrumpRx.gov, a new federal purchasing platform that is expected to go live next year.
In return, Pfizer will receive a three-year exemption from import tariffs on pharmaceutical ingredients, contingent upon expanding its domestic manufacturing operations. In this regard, PFE intends to invest an additional $70 billion over the next few years to strengthen its U.S. research and production footprint.
The above announcement has improved investor outlook around the overall pharma sector, as it signals a more cooperative stance between the Trump administration and Big Pharma. We view the Pfizer deal as a turning point that could ease regulatory and pricing pressures that have weighed on the industry since the onset of this year. Stocks of several major drugmakers, including AbbVie, moved higher last week on expectations that similar policy incentives and tariff exemptions could soon extend to other industry players, especially the ones that have already committed to investing billions to boost domestic investments.
Like Pfizer, AbbVie has also committed to a broader investment plan in the country. Earlier this year, the company announced plans to invest more than $10 billion over the next decade. Under this plan, ABBV recently announced a $70 million investment to increase the bioresearch and manufacturing capabilities at its Worcester, MA, facility. This new facility will boost domestic biologics manufacturing capacity to meet increased global demand and support U.S. production of current and next-generation oncology and immunology medicines.
Investors Express Optimism Around Pharma Sector
The Trump administration’s deal with Pfizer removed a major obstacle for the broader pharma industry. Besides AbbVie, shares of other pharma bigwigs like AstraZeneca (AZN - Free Report) and Eli Lilly (LLY - Free Report) , among others, also surged on the belief that they could follow PFE’s example and sign similar deals, largely benefitting the broader pharma sector. Both Lilly and AstraZeneca gained around 16% in the past week.
AstraZeneca announced plans to invest $50 billion in U.S. manufacturing and research and development (R&D) by 2030. AZN’s plan includes a new multi-billion-dollar manufacturing facility to be set up in Virginia.
Lilly has announced plans to invest $27 billion to develop four new manufacturing sites in the United States by 2025.
Several other companies like J&J, GSK, Novartis and Roche have also committed billions to U.S. manufacturing and R&D investments.
ABBV’s Price Performance, Valuation and Estimates
Shares of AbbVie have outperformed the industry year to date, as seen in the chart below.
Image Source: Zacks Investment Research
From a valuation standpoint, AbbVie is trading at a premium to the industry. Based on the price/earnings (P/E) ratio, the company’s shares currently trade at 16.91 times forward earnings, slightly higher than its industry’s average of 15.96. The stock is also trading above its five-year mean of 13.09.
Image Source: Zacks Investment Research
EPS estimates for 2025 and 2026 have increased in the past 60 days.
Image Source: Zacks Investment Research
AbbVie currently carries a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.